{
    "clinical_study": {
        "@rank": "144536", 
        "acronym": "MSREPAIR", 
        "arm_group": [
            {
                "arm_group_label": "olesoxime (TRO19622)", 
                "arm_group_type": "Experimental", 
                "description": "olesoxime (3 caps: 495 mg, od) will be administered orally as 165 mg soft capsules for 6 months.\nInvestigational products will be allocated in a 1:1 ratio from Baseline/Visit 0 to Week 24 (Visit 3/Final Visit)."
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo (3 soft capsules, od) will be administered orally for 6 months"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a 24-week phase 1b, randomized, double-blind, placebo-controlled, parallel-group,\n      multicenter safety study comparing the tolerance profile of olesoxime (495 mg, od) when\n      administered on top of Interferon beta in patients with stable Relapsing Remitting Multiple\n      Sclerosis. Patients will be randomly allocated to olesoxime (495 mg, od) or placebo in a 1:1\n      ratio."
        }, 
        "brief_title": "Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Relapsing Remitting Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis", 
                "Multiple Sclerosis, Relapsing-Remitting"
            ]
        }, 
        "detailed_description": {
            "textblock": "The primary objective of this study is to characterize the general safety and tolerability\n      of olesoxime (495 mg, od), compared to placebo when administered in combination with\n      Interferon beta over a 24-week treatment period in patients with stable Relapsing Remitting\n      Multiple Sclerosis.\n\n      The secondary objective of this study is to evaluate the feasibility of multicenter\n      protocols for measurement of neurodegeneration and remyelination by MRI as well as the\n      plasma exposure to olesoxime (495 mg, od).\n\n      MRI will be performed to all patients to assess effects of olesoxime on brain inflammation\n      as well as to assess measures of brain atrophy, neuronal damage and myelination status at\n      Baseline, 12 weeks and 24 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women \u2265 18 years old\n\n          -  Diagnosed with Relapsing Remitting Multiple Sclerosis. Patients must be stable\n             defined as free from relapsing episode for at least 6 months prior to Baseline\n\n          -  Patients must be treated with Interferon beta for at least one year\n\n          -  Patients must have an Expanded Disability Status Scale (EDSS) score \u2264 5\n\n          -  Female patients must be post-menopausal (defined as at least 12 months post cessation\n             of menses), surgically sterile or, if of childbearing potential, using a reliable\n             method of contraception for at least 3 months prior to Baseline and during the study.\n             In addition, female patients must not be lactating\n\n          -  Patients must be able to understand and comply with study requirements\n\n          -  Patients must provide a written, dated and signed informed consent prior to any study\n             procedure\n\n        Exclusion Criteria:\n\n          -  Any relapse of multiple sclerosis within the past 6 months prior to Screening\n             Visit/Visit -1\n\n          -  Any change in Interferon treatment within the past year prior to Screening Visit\n             (Visit -1)\n\n          -  Expected use of another disease modifying therapy from Screening Visit/Visit -1 to\n             Visit 3/Final Visit\n\n          -  Patients unable to undergo MRI scan\n\n          -  Current or expected use of a medication that could interfere with olesoxime\n             pharmacology (e.g. tamoxifen)\n\n          -  Current or expected use of lipid lowering agents (ezetimibe, bile salt chelators,\n             fibrates, phytosterols) other than statins\n\n          -  Known hypersensitivity to olesoxime or any of its components\n\n          -  History of alcohol or drug abuse within the last 6 months, or addiction within the\n             last 2 years prior to Baseline Visit\n\n          -  Positive urinary pregnancy test at Baseline Visit\n\n          -  History of hepatitis B/C or HIV positive serology\n\n          -  Hepatic impairment (aspartate aminotransferase (AST) and alanine aminotransferase\n             (ALT)> 3 \u00d7 ULN) at Baseline Visit\n\n          -  History of renal impairment defined by a serum creatinine value > 176 \u03bcmol/L (2.0\n             mg/dL) at Baseline Visit\n\n          -  Abnormal and clinically significant ECG at Screening Visit/Visit -1 as assessed by a\n             cardiologist\n\n          -  Current or expected use of oral or intramuscular corticosteroids within 3 months\n             prior to the Screening Visit. Only stable dose regimens of inhaled and topical\n             corticosteroids are allowed during the study\n\n          -  History of any clinically relevant gastrointestinal (GI), respiratory, psychiatric,\n             neurological, kidney, liver, cardiac diseases, bleeding disorder, other\n             disease/condition or abnormal physical finding which may interfere with the study\n             objectives or put the patient's safety at risk, as judged by the Investigator\n\n          -  Patients with an active chronic disease (or stable but treated with immune therapy)\n             of the immune system other than Multiple Sclerosis (MS)\n\n          -  History of malignancy of any organ, treated or non-treated within the past 5 years\n\n          -  Current participation or participation within 30 days prior to study entry, in\n             another investigational drug or device study, or previous enrolment in the present\n             study\n\n          -  Any direct involvement with the study conduct at site or any family link with study\n             site staff\n\n          -  Pregnant, parturient or lactating women, as per Public Health Code (CSP)(Article\n             L-1121-5)\n\n          -  Persons deprived of their liberty by a judicial or administrative decision, and those\n             admitted to a health or social facility, as per CSP (Article L-1121-6)\n\n          -  Persons covered by a measure of legal protection or unable to provide a written,\n             dated and signed informed consent, as per CSP(Article L-1121-8)\n\n          -  Patient without Social Security Insurance"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "44", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01808885", 
            "org_study_id": "TRO19622CLEQ1585-1", 
            "secondary_id": "2012-005186-12"
        }, 
        "intervention": [
            {
                "arm_group_label": "olesoxime (TRO19622)", 
                "description": "olesoxime (3 caps: 495 mg, od) will be administered orally as 165 mg soft capsules for 6 months.\nInvestigational products will be allocated in a 1:1 ratio from Baseline/Visit 0 to Week 24 (Visit 3/Final Visit).", 
                "intervention_name": "olesoxime (TRO19622)", 
                "intervention_type": "Drug", 
                "other_name": "TRO19622 (olesoxime)"
            }, 
            {
                "arm_group_label": "placebo", 
                "description": "placebo capsule shells with identical appearance as the active compound TRO19622", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-beta", 
                "Interferons"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "safety", 
            "multiple sclerosis", 
            "olesoxime", 
            "double-blind", 
            "randomized"
        ], 
        "lastchanged_date": "July 11, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France", 
                        "zip": "13385"
                    }, 
                    "name": "Timone University Hospital, Neurology Department, UMR CRMBM CNRS 6612"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Reims", 
                        "country": "France", 
                        "zip": "51092"
                    }, 
                    "name": "CHU Reims, Maison Blanche Hospital, Neurology Department & University of Reims"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rennes", 
                        "country": "France", 
                        "zip": "35033"
                    }, 
                    "name": "CHU Pontchaillou, Neurology Department"
                }
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "A 24-Week, Ph1b, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study, to Assess the Safety Profile of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.", 
        "other_outcome": {
            "description": "Exploratory Endpoints:\nThe following parameters will be assessed in terms of feasibility and reproducibility in a multicenter setting:\n3. Whole brain atrophy volume assessed by 3D-T1-weighted images. 4. Demyelination and remyelination processes assessed by Diffusion Tensor Imaging.\n5. Remyelination processes assessed by Magnetization Transfer Ratio. 6. Neuroaxonal damage assessed by sodium 23 imaging in one center.", 
            "measure": "Exploratory MRI Parameters", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline (Visit 0), Week 12 (Visit 2) and Week 24 (Visit 3/Final Visit)"
        }, 
        "overall_official": [
            {
                "affiliation": "Head of Neurology Department, UMR CRMBM CNRS 6612, Timone University Hospital, Marseille, France", 
                "last_name": "Jean PELLETIER, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Professor of Neurology, Neurology Department & University of Reims", 
                "last_name": "Ayman TOURBAH, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Professor of Clinical Neurology, Head of Neurology Department, Pontchaillou Hospital, Rennes, France", 
                "last_name": "Gilles EDAN, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Cumulative incidence of adverse events/serious adverse events (i.e. total number per patient) as assessed by ongoing monitoring.", 
            "measure": "Safety criteria", 
            "safety_issue": "Yes", 
            "time_frame": "The primary endpoint of this study will be the cumulative incidence of AE/SAE assessed by ongoing monitoring at week 24 (day 168)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01808885"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Number of Gadolinium-enhancing lesions on T1-weighted images\nNumber of new or enlarged lesions on T2-weighted images", 
            "measure": "MRI Parameters", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline (Visit 0), Week 12 (Visit 2) and Week 24 (Visit 3/Final Visit)"
        }, 
        "source": "Trophos", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "H\u00f4pital de la Timone (UPCET/CIC)", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "SGS", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "STRAGEN Services", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Trophos", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}